Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma. Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression. Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.
Location: Spain, Autonomous Community of the Basque Country, Derio
Employees: 11-50
Total raised: $42.5M
Founded date: 2009
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.01.2025 | - | $26.3M | - |
| 18.04.2022 | - | $16.2M | - |
Mentions in press and media 10
| Date | Title | Description |
| 29.01.2025 | Oncomatryx Secures €25 Million to Propel Cancer Research Forward | In the world of biopharmaceuticals, funding is the lifeblood that fuels innovation. On January 27, 2025, Oncomatryx, a biopharmaceutical company based in Zamudio, Spain, announced a significant milestone: the successful raising of €25 milli... |
| 27.01.2025 | Oncomatryx Raises €25M in Funding | Oncomatryx, a Zamudio, Spain-based biopharmaceutical company developing novel ADCs against the tumor microenvironment, raised €25M in funding. The round was led by existing investors and included a €10M strategic investment from Centro para... |
| 27.01.2025 | ONCOMATRYX Raises €25 Million to Foster OMTX705 Clinical Trials | ZAMUDIO, Spain–(BUSINESS WIRE)–January 27, 2025– ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-... |
| 19.05.2023 | Oncomatryx Acquires Tube Pharmaceuticals | Oncomatryx, a Zamudio, Spain-based global bio-pharmaceutical company, acquired Tube Pharmaceuticals GmbH, the Austrian developer of the Cytolysintoxic payload. The amount of the deal was not disclosed. The multimillion euro transaction is a... |
| 18.05.2023 | Oncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment | ZAMUDIO, Spain–(BUSINESS WIRE)–May 18, 2023– Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload. The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its lead... |
| 31.05.2022 | Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors | BILBAO, Spain–(BUSINESS WIRE)–May 31, 2022– After 15 years of pioneering R&D efforts in the tumor microenvironment, Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) ap... |
| 19.04.2022 | Oncomatryx Announces a €15 Million Capital Increase to Conduct Clinical Trials Against the Tumor Micro-environment | BILBAO, Spain–(BUSINESS WIRE)–April 19, 2022– Following 12 years of pioneering research activities, Oncomatryx is embarking on a new phase in the development of its tumor microenvironment – targeted ADCs. OMTX705, the Crown Jewel, has alrea... |
| 09.01.2019 | Oncomatryx cierra una ronda de €9M, acuden accionistas actuales, Ekarpen, BBK y FO vascos y gallegos | 09/01/2019 Nota de prensa ONCOMATRYX CIERRA UNA RONDA DE €9 MILLONES, ACUDEN ACCIONISTAS ACTUALES, EKARPEN, BBK Y FAMILY OFFICES VASCOS Y GALLEGOS. La empresa de biotecnología Oncomatryx ha realizado una ampliación de capital de 9 millon... |
| 16.12.2015 | GCRPV acude a la ampliación de capital de €4,5M de la biotecnológica Oncomatryx | 16/12/2015 GCRPV ACUDE A LA AMPLIACIÓN DE CAPITAL DE €4,5 MILLONES DE LA BIOTECNOLÓGICA ONCOMATRYX. La biotecnológica española Oncomatryx, ha cerrado una ronda de €4,5 millones en el marco de una ampliación de capital suscrita por inverso... |
| - | Oncomatryx | “Oncomatryx Biopharma focuses on target cancer associated stroma developing precision drugs.” |